First Albany Companies News

Broadpoint Capital, Inc., a broker-dealer subsidiary of Broadpoint Gleacher Securities Group, Inc.

December 16, 2009 DFacet Biotech Corporation trading at $16.07 on a volume of 742,804 shares In a press release on December 16, Facet Biotech Enters Agreement With The Baupost Group to Allow Purchase of Additional Shares REDWOOD CITY, CA, Dec 16, 2009 Facet Biotech Corporation today announced that in response to a request from The Baupost Group, ...

As of Dec. 16, Baupost held a 14% position in Facet. Under a new amendment to Facet's Rights Agreement, Baupost will be able to own up to 20% of Facet's float.

The study... NORTH AUGUSTA, S.C.-- --The Lightstone Group announced today that Sonic Drive-In has signed a 40,000-square-foot, long-term lease at its Martintown Plaza shopping center in North Augusta... NEW YORK-- --Certain BlackRock closed-end funds announced distributions today as detailed below.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Main Category: Melanoma / Skin Cancer Also Included In: Pharma Industry / Biotech Industry Clinical Trials / Drug Trials Facet Biotech Corporation and Bristol-Myers Squibb Company announced that potentially promising data from a Phase I/II study of elotuzumab, an investigational humanized antibody being studied for the treatment of relapsed ...

Biogen has offered to pay $17.50 a share in cash for Facet, upped from its previous bid of $14.50 a share.

Three months of volleying over a takeover bid by Biogen Idec Inc. will come to a head next week, when Facet Biotech Corp.

Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Pharma Industry / Biotech Industry Clinical Trials / Drug Trials Trubion Pharmaceuticals, Inc.

Clinical activity seen for elotuzumab plus lenalidomide and low dose dexamethasone Results support initiation of global Phase II study REDWOOD CITY, Calif.

There are two rules in negotiations. Don't be the first to name a number and don't get in a bidding war with yourself.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Shares of the following companies may have unusual moves in U.S. trading. Stock symbols are in parentheses, and prices are as of 9 a.m. in New York.

Biogen Idec Inc. today announced that it has increased its offer to purchase all of the outstanding shares of Facet Biotech Corporation to $17.50 per share in cash, representing an increase of $3.00 per share, or 21%, over its previous offer.

Together, we are all trying to build our fortune by finding well-run companies at bargain-basement prices.

"We are executing on our development programs while remaining vigilant on cost containment and expense management," said Faheem Hasnain, president and chief executive officer of Facet Biotech.

Among the companies whose shares are expected to see active trade in Monday's session are Allion, Apple, Eaton, Facet Biotech, Hasbro, InterDigital, Nokia, Pfizer, TI and Weatherford.

Biotech has traditionally been a sector that has fared better than most during economic downturns.

Facet Biotech By Merriman Curhan Ford WE WHOLEHEARTEDLY agree with Facet Biotech management that the offer from Biogen Idec is inadequate and not in the best interest of shareholders.

Broadpoint Capital, Inc., a broker-dealer subsidiary of Broadpoint Gleacher Securities Group, Inc.